Concepedia

Sergey Alekseev

SA

6

Publications

1.2K

Citations

6

H-Index

2014

Active since

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

University of Bologna

Memorial Sloan Kettering Cancer Center

Centre Antoine Lacassagne

Institute of Oncology NN Petrov

Sergey Alekseev is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in radiation oncology, pathology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2014–2021

6

Publications

6

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 738 citations · Full text

The microRNA-15 family inhibits the TGFβ-pathway in the heart

Anke J. Tijsen, Ingeborg van der Made, Maarten M.G. van den Hoogenhof et al. · Cardiovascular Research · 2014 · 162 citations · Full text

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors et al. · The Lancet Haematology · 2021 · 153 citations

, , +8

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev et al. · Blood · 2020 · 109 citations · Full text

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · Journal of Clinical Oncology · 2020 · 34 citations

, , +18

Rows per page

1–5 of 6